Serum antibody response to matrix protein 2 following natural infection with 2009 pandemic influenza A(H1N1) virus in humans

Journal of Infectious Diseases

Volumn 209, Issue 7, 2014, Pages 986-994

  Zhong, Weimin ^a   Reed, Carrie ^a   Blair, Patrick J ^b   Katz, Jacqueline M ^a   Hancock, Kathy ^a   Aranio, Darbi ^c   Bai, Yaohui ^c   Browning, Peter ^c   Branch, Alicia ^c   Steward Clark, Evelene ^c   Cronin, Li ^c   Dababneh, Hanan ^c   Gillis, Eric ^c   Holiday, Crystal ^c   Liu, Feng ^c   Lu, Xiuhua ^c   Tatum, Heather R ^c   Quinn, Conrad ^c   Soroka, Stephen ^c   Schiffer, Jarad ^c   Sun, Hong ^c   Thomas, Leilani ^c   Tsang, Byron ^c   Veguilla, Vic ^c   Wang, David ^c   Whaley, Melissa ^c   more..

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c NONE

Author keywords

Antibody; Human; Influenza A virus; Matrix protein 2

Indexed keywords

MATRIX PROTEIN; MATRIX PROTEIN 2; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; AGE; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CROSS REACTION; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEASONAL INFLUENZA; SEROPREVALENCE; UNITED STATES;

ANTIBODY; HUMAN; INFLUENZA A VIRUS; MATRIX PROTEIN 2;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CROSS REACTIONS; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; UNITED STATES; VIRAL MATRIX PROTEINS; YOUNG ADULT;

EID: 84899015862     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit811     Document Type: Article

References (42)

1. Wright PF, Webster RG. Orthomyxoviruses. In Knipe DM, Howley PM, ed. Fields virology. Philadelphia: Lippincott William & Wilkins, 2001:1533-79
2. Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol 1983; 37:529-49
3. Allan WH, Madeley CR, Kendal AP. Studies with avian influenza A viruses: Cross protection experiments in chickens. J Gen Virol 1971; 12: 79-84
4. Epstein SL, Misplon JA, Lawson CM, et al. Beta 2-microglobulindeficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase. J Immunol 1993; 150:5484-93. (Pubitemid 23180662
5. Francis T, Salk JE, Quilligan JJ. Experience with vaccination against influenza in the Spring of 1947: A preliminary report. Am J Public Health Nations Health 1947; 37:1013-6
6. Kilbourne ED, Smith C, Brett I, et al. The total influenza vaccine failure of 1947 revisited: Major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic. Proc Natl Acad Sci U S A2002; 99:10748-52
7. Fedson DS, Huber MA, Kasel JA, et al. Presence of A-Equi-2 hemagglutinin and neuraminidase antibodies in man. Proc Soc Exp Biol Med 1972; 139:825-6
8. Zebedee SL, Richardson CD, Lamb RA. Characterization of the influenza virus M2 integral membrane protein and expression at the infectedcell surface from cloned cDNA. J Virol 1985; 56:502-11. (Pubitemid 16192338
9. Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell 1992; 69:517-28
10. Zebedee SL, Lamb RA. Influenza A virus M2 protein: Monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 1988; 62:2762-72
11. Feng J, Zhang M, Mozdzanowska K, et al. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 2006; 3:102
12. Black RA, Rota PA, Gorodkova N, et al. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J Gen Virol 1993; 74(Pt 1):143-6. (Pubitemid 23053779
13. Liu W, Li H, Chen YH. N-Terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol Med Microbiol 2003; 35:141-6. (Pubitemid 36298936
14. Fu TM, Grimm KM, Citron MP, et al. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 2009; 27:1440-7
15. Fu TM, Freed DC, Horton MS, et al. Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Virology 2009; 385:218-26
16. Grandea AG III, Olsen OA, Cox TC, et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza Aviruses. Proc Natl Acad Sci U S A 2010; 107:12658-63
17. Wang R, Song A, Levin J, et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 2008; 80:168-77
18. Jegerlehner A, Schmitz N, Storni T, et al. Influenza A vaccine based on the extracellular domain of M2: Weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004; 172:5598-605. (Pubitemid 38542062
19. Neirynck S, Deroo T, Saelens X, et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999; 5:1157-63. (Pubitemid 29474420
20. Song JM, Wang BZ, Park KM, et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 2011; 6:e14538
21. Mozdzanowska K, Zharikova D, Cudic M, et al. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol J 2007; 4:118
22. Reed C, Katz JM, Hancock K, et al. Prevalence of seropositivity to pandemic influenza A/H1N1 virus in the United States following the 2009 pandemic. PLoS One 2012; 7:e48187
23. Bautista E, Chotpitayasunondh T, Gao Z, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:1708-19
24. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935-44
25. Jhung MA, Swerdlow D, Olsen SJ, et al. Epidemiology of 2009 pandemic influenza A (H1N1) in the United States. Clin Infect Dis 2011; 52 (Suppl 1):S13-26
26. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361: 1945-52
27. Ge X, Tan V, Bollyky PL, et al. Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swineorigin influenza Avirus. J Virol 2010; 84:3312-9
28. Greenbaum JA, Kotturi MF, Kim Y, et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 2009; 106:20365-70
29. Scheible K, Zhang G, Baer J, et al. CD8+ T cell immunity to 2009 pandemic and seasonal H1N1 influenza viruses. Vaccine 2011; 29: 2159-68
30. Zhong W, He J, Tang X, et al. Development and evaluation of an M2-293FT cell-based flow cytometric assay for quantification of antibody response to native form of matrix protein 2 of influenza A viruses. J Immunol Methods 2011; 369:115-24
31. National Health and Nutrition Examination Survey. 2008. http://www. cdc.gov/nchs/nhanes.htm. Accessed 28 March 2011
32. Veguilla V, Hancock K, Schiffer J, et al. Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol 2011; 49: 2210-5
33. Serological diagnosis of influenza by haemagglutination inhibition testing. In: Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva: WHO, 2011:59-62
34. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of Swine-Origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325:197-201
35. Smith GJ, Vijaykrishna D, Bahl J, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009; 459:1122-5
36. Sandbulte MR, Jimenez GS, Boon AC, et al. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007; 4:e59
37. Treanor JJ, Tierney EL, Zebedee SL, et al. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 1990; 64:1375-7. (Pubitemid 20087784
38. Tompkins SM, Zhao ZS, Lo CY, et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007; 13:426-35. (Pubitemid 46348126
39. Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, et al. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol 2002; 83:1851-9. (Pubitemid 34846448
40. Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. Curr Top Microbiol Immunol 2009; 333:43-82
41. El Bakkouri K, Descamps F, De Filette M, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011; 186: 1022-31
42. Song JM, Van Rooijen N, Bozja J, et al. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A 2011; 108:757-61